ABT-263 (CAS: 923564-51-6)

Catalog #: EBC51003

Biological Activity

Synonyms	Navitoclax, ABT263, ABT 263
Chemical Name	(R)-4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((4-((4-morpholino-1-(phenylthio)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonyl)benzamide
Application	ABT-263 is a bcl-2 family protein inhibitor
CAS No.	923564-51-6
Purity	≥99%
Molecular Weight	974.61
Molecular Formula	$C_{47}H_{55}ClF_3N_5O_6S_3$
Shipping	Gel Pack
Storage	Store at -20° C
Target & IC_{50}	EOL1: IC50 = 6.69 nM
	NKM-1: IC50 = 16.99 nM
	ML-2: IC50 = 19.83 nM
	BV-173: IC50 = 23.14 nM

Molecular Structure



Solubility

DMSO: 100 mg/mL (102.6 mM)

PS: < 1 mg/ml refers to the product insoluble

Description

ABT-263 is a novel inhibitor of antiapoptotic BCL-2 proteins and a new promising anticancer drug candidate. ABT-263 is active against approximately one-half of the cell lines of the PPTP in vitro panel. The median IC50 for all of the lines in the panel is 1.91 μM. Navitoclax in combination with chemotherapy agents leads most ovarian cancer cell lines a synergistic response, and enhances the caspase activation in both SK-OV-3 and IGROV-1 cell lines.

EbioCell Lifescineces, Inc.
Imperial Business Park 4819 Emperor Boulevard,
Suite 408 Durham, NC 27703, USA

Order: order@ebiocell.com
TEL: (540)808-3925
Supprt: tech@ebiocell.com